We are a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types, with our multi-national R&D centers established in New Jersey and Hangzhou. With a strategic emphasis on oncology, we have identified and developed a robust pipeline of six drug candidates.
We have assembled a management team and a scientific advisory board with industry leaders and influential scientists, who provide international and strategic guidance to our R&D, business development, and operational teams. In addition to building our own R&D capabilities, we continue to seek and secure partnerships with leading multi-national pharmaceutical companies such as Eisai Co., Ltd. or Eisai and Novartis Pharma AG or Novartis, to fully realize the potential of our pipeline programs. We are committed to becoming an innovative biotechnology company with global vision and strives to benefit patients worldwide. Our ultimate goal is to transform deadly cancer into a chronic and eventually curable disease.
Option Agreement with Nippon Kayaku for AN2025
The first patient dosed in phase I clinical trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for advanced tumors
Publication of preclinical research of AN3025 (anti-hTNFR2）in Frontiers in Immunology
The first patient was dosed in China for the global Phase III clinical trial of AN2025 in combination with paclitaxel for the treatment of patients with recurrent or metastatic HNSCC
Five international renowned experts joining our Scientific Advisory Board as the initial members
Raised US$97.4 million in series D investments
Obtained IND clearance for AN4005 for the treatment of advanced tumors from the FDA
Raised approximately US$63.7 million in series C investments
Entered global clinical collaborations with partner A to evaluate a triple combination of AN2025 (buparlisib), AN0025 and Tecentriq®
Received the approval from the NMPA to initiate a Phase III multi-center clinical trial of AN2025 in combination with paclitaxel for the treatment of patients with recurrent or metastatic HNSCC
The first patient was dosed in the United States for Phase Ib clinical trial of AN0025 in combination with Keytruda
AN1004 received an approval from the NMPA for our initiation of a phase III clinicaltrial for AN1004 in combination with paclitaxel in patients with HR+/HER2- mBC
Entered global clinical collaboration with partner B to evaluate the combination of AN0025 and Keytruda for the treatment of solid tumors
Presented encouraging phase Ib study data of AN0025 at ESMO Congress 2019
Obtained the multi-national rights of E7046 (AN0025) through our in-licensing agreement with Eisai and took over the phase Ib clinical trial study of AN0025 from Eisai
Adlai Nortye (US) was incorporated
Raised approximately US$52.8 million in series B investments
Raised approximately US$5.4 million in series A investments
Hangzhou subsidiary was
converted into a joint stock limited company
Rebranded as Adlai Nortye Biopharma and transformed into clinical stage biotechnology company focusing immuno-oncology products
Adlai Nortye Biopharma (formerly known as Hangzhou Nuotai Pharmaceutical Co., Ltd.) was established
浙公网安备 33011802000947号
|
Privacy Policy
